Following subsequent network pharmacological analyses, pivotal targets of GQD for the concurrent treatment of T2DM and UC were identified, including AKT1, BCL2, EGFR, ESR1, PTGS2, STAT3, and TNF. The gene discussed is PTGS2; the disease is type 2 diabetes mellitus.